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Abstract
There are more than 8000 rare diseases (RDs) that affect >5 % of the world’s population. Many of the RDs have no
effective treatment and lack of knowledge creates delayed diagnosis making management difficult. The emerging
concept of the personalized medicine allows for early screening, diagnosis, and individualized treatment of human
diseases. In this context, the discovery of biomarkers in RDs will be of prime importance to enable timely prevention
and effective treatment. Since 80 % of RDs are of genetic origin, identification of new genes and causative mutations
become valuable biomarkers. Furthermore, dynamic markers such as expressed genes, metabolites, and proteins are
also very important to follow prognosis and response the therapy. Recent advances in omics technologies and their
use in combination can define pathophysiological pathways that can be drug targets. Biomarker discovery and their
use in diagnosis in RDs is a major pillar in RD research.
Keywords: Rare diseases, Biomarker panels, Multi-omics, Predictive preventive personalized medicine, Innovation,
Prognosis, Screening, Individualized therapy, Biobank, Drug targets
Background
Diseases defined as “rare” have a very low prevalence;
with EU definition of 1 patient per 2000 individuals. In
EU, it is estimated that about 6–8 % of the population is
affected with rare diseases (RDs) which makes about 30
million individuals. Worldwide, there are about 350–400
million rare disease patients (https://globalgenes.org/rare-
diseases-facts-statistics).
Even if a single RD has a low prevalence, there are
more than 8000 different diseases which make them a
formidable health problem. About 80 % of RDs have a
genetic origin and affect pediatric age group even
though there are diseases that manifest at later ages.
Most RDs are very severe, chronic, and life threatening
and have not yet been well characterized. There is a gen-
eral lack of knowledge which makes diagnosis difficult
and most of the patients receive a very delayed diagnosis
after consulting with multiple healthcare centers. Due to
low numbers, clinical trials are challenging and
development of drugs has been hampered since these
diseases have not caught the attention of large pharma-
ceutical companies.
In recent years, there are national and international
initiatives to accelerate research for timely diagnosis and
development of new therapies for RDs [1] (http://
www.ema.europa.eu/ema/index.jsp?curl=pages/special_to-
pics/general/general_content_000034.jsp).
European activities for rare diseases
In 2008, European Commission has published a communi-
cation (COM 679/2) indicating challenges of RDs and sets
a strategy for increasing the visibility of and the cooperation
and coordination for RDs in Europe. This recommendation
has initiated the formulation of national plans for rare dis-
eases in the member states. Furthermore, regulatory bodies
such as European Medicinal Agency (EMA) [2] in EU and
EC Orphan Drugs Regulation that European Parliament
and the Council adopted [(CE) No. 141/2000, (CE) No.
847/2000] and 1983 Orphan Drugs Act in the USA [3] are
supporting the development of orphan drugs through dif-
ferent incentives for the pharmaceutical companies.
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International activities for rare diseases
A most recent development is the initiative “The
International Rare Diseases Consortium (IRDiRC)” “by
the collaborative action of USA, Canada, and EU”,
IRDiRC aims to foster collaborative research efforts
and harmonize policy for accelerating diagnosis and
therapy of rare diseases. The consortium has set the
following general goals: “establishing and providing
access to harmonized data and samples, performing
the molecular and clinical characterization of rare diseases,
boosting translational, preclinical and clinical research,
streamlining ethical and regulatory procedures.” without
the mission of finding 200 new therapies and diagnosis of
all RDs by the year 2020 [4].
Altogether, the roadmap for a concerted action for
RDs needs infrastructures for well-characterized and or-
ganized collections of biological samples (biobanks) for
biomarker discovery, patient registries with well-defined
phenotypes that are linked to the biological samples and
omics platforms (genomics, transcriptomics, proteomics,
metabolomics) that will help to uncover the pathophysi-
ology of still uncharacterized diseases. In vitro and in vivo
models will aid to annotate the function of the newly dis-
covered genes and the development of new modalities of
therapies. Moreover, bioinformatics tools are essential to
harmonize the high-throughput data generated by the
omics platforms.
The impact of personalized medicine approach on
health care is being felt already in clinical practice. The
use of integrated omics technologies is the driving force
in personalized medicine for biomarker discovery. The
development of genetic tests based on biomarker discov-
ery will be basic accelerators for better diagnosis and tar-
geted therapies in RDs [5–7].
Types of biomarkers
A biomarker in general denotes characteristics assigned
to a biological state and/or change. While this may in-
clude physical methods, such as EEG or ECG, biomarker
in a more confined biomedical context comprise biological
entity(ies) that can be used for the diagnosis, prognosis of
disease, and individual’s response to drugs or therapies (a
characteristic that is objectively measured and evaluated
as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic
intervention) [8]. The following parameters are indicators
of a biomarker that is reliable and is valuable in the clinical
setting.
1) A biomarker needs to have a clinical and analytical
validity.
2) It should be measured by tests that are reliable,
accurate, and reproducible and should distinguish
between the pathological and healthy state.
3) The biomarker should also be able to indicate any
changes in the status of the disease and the disease
development in a stable manner and not be
influenced by outside parameters. A clinically
validated biomarker should indicate the prognosis
of a disease or an individual’s response to a drug.
In rare diseases that have a genetic origin, causative
genes, disease-causing mutations, polymorphisms, and
phenotypic dynamic markers, i.e., RNA/miRNAs, pro-
teins, and metabolites that can change over time are all
considered valuable biomarkers to identify/characterize
the disease as well as the cellular pathophysiology. For
clinical utility, biomarkers should be measured in bio-
logical samples obtained by non-invasive methods such
as urine, stool, plasma, serum, and saliva rather than bi-
opsies. Ideally, the biomarker activity needs to remain
stable in the biological sample used [9, 10].
The major goals in the RDs research are molecular
classification, identification of new genes, and deter-
mination of causative mutations, biomarker discovery,
development of new diagnostics and therapies, and
establishment of high-quality sample biobanks and
patient registries. It goes without saying that a bio-
marker for a complex disease nowadays usually com-
prises several characteristics, such as a combination
of metabolites, transcripts, or peptides.
Genomics and transcriptomics
Initial gene identification studies relied on the large
families with multiple affected individuals. Using this
approach, mapping a genomic interval means that
many genes in this region need to be sequenced to
find the mutation responsible for the disease that
segregates in the family. The positional cloning ap-
proach relied on the genomewide use of microsatellite
markers or SNPs. In populations where inbreeding
ratio is high, homozygosity mapping is a valid
approach for identification of genes in autosomal
recessive (AR) monogenic diseases [11].
The latest advances in genetic technologies are facili-
tating the use of whole-exome (WES) or whole-genome
sequencing (WGS) for identification of disease genes
[12]. Coupled with advanced bioinformatics techniques,
this approach is being used successfully in RDs research
and is also entering the clinic for diagnostic purposes.
The advantage of WES approach is that it is faster and
cheaper than WGS. The exonic sequences that make up
about 1 % of the genome are reported to harbor more
than 80 % of the disease-causing mutations [13]. The ad-
vantage of the WGS approach is that by this technique,
all exons and non-coding genomic sequences are cov-
ered and structural variations can also be detected. The
identification of non-coding genomic variations that
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can act as modifier can be informative for explanation
of discordant spectrum of phenotypes that is frequently
observed in rare diseases [14].
Cellular gene expression patterns are known to change
in health and disease. Global transcriptome assays now
can be done using the RNA-Seq technology that utilizes
the next generation sequencing methodology. Besides
detecting cDNA sequences, the method is also capable
of detecting miRNAs. miRNAs are non-coding short
(20–22 nucleotides) RNA molecules that are involved in
the regulation of cellular pathways. In this respect, they
have emerged as valuable diagnostic biomarkers and
they can also be used as markers with respect to the re-
sponse to therapy [15]. A recent study has shown that
circulating miRNAs are found to be elevated in serum of
patients with Duchenne and Becker muscular dystrophies.
The level of the identified miRNAs decreased after exon
skipping therapy and restoration of dystrophin protein [16].
Another rare disease where alterations in miRNAs
have been observed is Rett syndrome, a severe neuro-
logical disorder. It has been observed that significant alter-
ation of miRNA expression patterns occurs in mice with
disease-causing mutations in the Mecp2 protein [17]. As
next generation sequencing technologies (NGS) are more
commonly used, it is expected that the identification of
miRNAs as circulating biomarkers will facilitate the thera-
peutic and prognostic testing in rare diseases.
Metabolomics
Rare diseases are a heterogeneous group of diseases with
small number of patients that need better analytical
tools and approaches for diagnosis and treatment. Un-
fortunately, many undiagnosed cases are fatal, and a
large group of these patients are affected with neurome-
tabolic symptoms. Metabolomics as an approach has the
advantage to detect alterations and deficiencies in the
metabolic state that is a cellular marker for as a molecular
signature. Since body fluids can be used for metabolomics,
it is a non-invasive approach that can lead to new diagno-
sis and grading of the disease. Also, the identification of
the affected biochemical pathways can act as targets for
drug discovery which is still in the management of rare
diseases.
Metabolomics is defined as the global systematic study
of the unique chemical fingerprint end products of the
metabolic transformations that occur in the biological
systems [18, 19]. As the newest member of the omics
family, metabolome refers to the low-molecular weight
(<1500 Da) molecules such as amino acids, lipids, carbo-
hydrates, biogenic amines, and organic acids that bio-
chemical reactions leave behind [20]. Cellular pathways
can be followed on a real time basis by metabolomic
studies, and it better reflects the actual metabolic state
of a cell, tissue or organ, translating the genotype and
environmental factors into the phenotype. Therefore,
metabolites usually serve as a clinical endpoint and de-
lineate the disease mechanisms and reflect the under-
lying biochemistry [21]. It is for this reason that many
metabolites are also used as biomarkers for different dis-
eases. Metabolome consists of different molecule classes
that have very different chemical structures. Accordingly,
no single analytical tool is able to cope with the huge
chemical diversity of the metabolome. Multiple analytical
tools are needed to get a comprehensive and complete pic-
ture of the whole metabolome. Although many different
analytical tools are used in metabolomics, nuclear mag-
netic resonance (NMR) [22] and mass spectrometry (MS)
[23] stand out as the most powerful and information-rich
techniques. In NMR, samples are directly analyzed with
minimal sample preparation. This technique eliminates
the time-consuming separation and derivatization steps
and is also a non-destructive technique. Moreover, the
features of different metabolites are quite distinguishable
especially when high magnets are used. However, the rela-
tively poor sensitivity of NMR (mM to high uM), require-
ment of high sample volumes (high uL to ml range), and
very high instrument costs are still the main drawbacks of
this technique. The other primary tool used in metabolo-
mics is gas or liquid chromatography equipped with mass
spectrometry (GC-MS and LC-MS). Both GC-MS and
LC-MS are quite sensitive (uM to nM range) and amen-
able to automation. On contrary to NMR spectroscopy,
very low sample volumes (uL) are required in mass spec-
trometric methods. This technique became particularly
useful in studies involving human subjects where biological
samples amount is an issue. Today, MS has therefore
become the method of choice for many metabolomics
laboratories worldwide. In some recent studies, NMR
spectroscopy is used orthogonally to mass spectrometry
techniques to improve the metabolome coverage and
get a more detailed picture [24].
Metabolomics methods
Metabolomics studies are usually condensed into two
main categories as targeted and untargeted metabolomics.
In untargeted metabolomics, the question of “which metab-
olite(s) are different in particular sets of samples” is an-
swered. Untargeted metabolomics provides an unbiased
and global profile of the samples, and these profiles are
used to extract statistically different metabolites between
control and test samples. Following stringent bioinformatic
analyses and database search, the evolved data is linked to
biochemical pathways, and therefore this approach is also
known as “hypothesis generating metabolomics”. Upon de-
termining statistically significant metabolites, they are then
subjected to validation. Untargeted global profiling is also
named as “next generation metabolomics” akin to “next
generation sequencing” [25].
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In targeted metabolomics, as its name implies, certain
metabolites are predefined and these metabolites are
probed across different samples to determine their fold
changes. The question of “if the quantity of a certain
metabolite(s) is different in two different states” is an-
swered. Unlike untargeted metabolomics, prior biochem-
ical knowledge is used to define the metabolites to be
quantified. This method is used complementary to the
untargeted metabolomics to validate putative biomarkers.
As it is biased towards the metabolites of choice, it is very
selective, much faster and greater sensitivities can be
attained [26].
Metabolomics in rare disease diagnosis and
characterization
While metabolomics is a fairly new omics area, the idea
of using metabolites for screening rare diseases is indeed
quite established. In 1960s, Robert Guthrie introduced
the bacterial inhibition assay, and this assay is still being
used as a semiquantitative technique in early screening
of phenylketonuria. After the development of triple
quadrupole mass spectrometers, such kind of assays
were replaced by mass spectrometry methods. This tech-
nique which is commonly known as “tandem MS” in
clinical lab practice essentially relies on the “targeted
metabolomics” principles. If disease-specific metabolites
are known, then MS assays for these “targets” can be
very specifically developed [27, 28].
The main advantage of this approach is that many
diseases can be screened in a single experimental run
simultaneously. For the past two decades, tandem mass
spectrometry has been used for screening well over 60
different diseases and identified clinical biomarkers can
be used to explain the pathological phenotypes. Rare
diseases including inborn errors of metabolism are the
prime examples of those groups of diseases.
Organic acidemias, amino acid disorders, fatty acid
oxidation defects, congenital disorders of glycosylation,
and lysosomal storage diseases can now be routinely
screened by specific MS methods. Henceforth, MS be-
came the centerpiece instrumentation of clinical labora-
tories. A list of some rare metabolic diseases that could
be diagnosed by targeted metabolomics is illustrated in
Table 1 [29].
Data analysis
The analysis of all kind of omics data consists of similar
steps. It starts with a thorough quality control of the raw
Table 1 Disease-specific analytes by targeted metabolomics
Diseases Disease-specific analytes
PKU Phe
MSUD [Leu + Ile] and Val, alloisoleucine
Homocystinuria Met
Citrullinemia I, argininosuccinic aciduria, citrin deficiency Cit
OTC deficiency, CPS1 deficiency Cit (low)
Arginase deficiency Arg
Tyrosinemia Tyr
Systemic carnitine deficiency C0 (low)
CPT1 deficiency C0 (high)
Methylmalonic aciduria, propionic aciduria, cobalomanine defects C3
SCAD deficiency, IBD deficiency C4
SCHAD (HAD) deficiency, ketosis C4-OH
Isovaleric acidemia C5
Glutaric aciduria type 1 C5-DC
Glutaric aciduria type 2 C4-C18
Multiple carboxylase deficiency, 3-methylcrotonylglycinuria, 3-methylglutaconicaciduria I,
3-oxothiolase, HMG uria, beta-ketothiolase deficiency, biotinidase deficiency
C5-OH
MCAD deficiency C6, C8-C10-C10:1
VLCAD deficiency, ketosis C12, C12:1, C14, C14:1, C14:2, C16, C18, C18:1
CPT2 deficiency C16, C18:1, C18:2
TFP C14, C14:1, C14:2, C16-OH, C16:1-OH, C18:1, C18:2
LCHAD C14, C14:1, C14:2, C16-OH, C16:1-OH, C18:1, C18:2
CACT deficiency C18:1(C18)
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data. Next, one or more preprocessing steps are applied
to the raw data. This is also called low-level analysis and
for instance can include background/baseline correction
and normalization. The goal of preprocessing is to ac-
count for the various sources of variation which are
immanent in omics experiments. It is necessary as
many statistical procedures rely on homoscedasticity
or distributional assumptions which are surely not ful-
filled for the raw data [30]. Then, the actual statistical
analysis is conducted using the preprocessed data. Here,
all kind of uni- and multivariate statistical methods are ap-
plied dependent on the question at hand. There are associ-
ated statistical method dependent recent developments in
genomics [31]. The analysis of high-dimensional omics
data, however, can be quite challenging especially because
of the “large p, small n” problem; that is, the number of
features/variables (e.g., genes, metabolites, etc.) in such
omics data sets is as a rule (much) larger than the number
of observations [32]. There are statistical challenges of
high-dimensional data [33]. Finally, information from
various databases is added to the features obtained by the
statistical analysis. First, one assigns various categories
(provided by the databases) to the features where the cat-
egories are based on, e.g., functional, biological, chemical,
health, etc. information [34, 35]. Then, by applying the so-
called enrichment methods, one identifies the categories that
are over-represented; that is, include more features than one
would expect by chance [36, 37]. These over-represented
categories represent specific properties of the features identi-
fied in the statistical analysis and enable a deeper under-
standing and further interpretation of the results.
Biobanks for rare diseases
Omics technologies require the use of well-annotated
biological samples of high quality. Biobanks that meet
the quality assurance criteria and with sound ethical and
legal guidelines are valuable infrastructures that house
biological samples as well as the clinical data associated
with the samples. Recent developments have led to
networking activities in biobanks across Europe. EU
has supported the formation of European Research In-
frastructure Consortiums (ERICs) [38] and Biobanking
and BioMolecular Resources Research Infrastructure
(BBMRI-ERIC) [39] is a pan-European platform of
member and observer states towards creation of and
sharing of the best practice guidelines as well as harmo-
nized ethical legal and social issues (ELSI) that will enable
sharing of samples and data across the EU borders.
BBMRI gained legal status in 2013 and main advantage of
ERICs as governance structures will be a long-term co-
operation among states that will enable sustainability
which is crucial in biobanking activities.
In rare diseases, a well-established network in bio-
banking activity is EuroBioBank. Twenty one biobanks
from nine European countries are currently members of
The EuroBioBank. The primary goals of the network are
as follows “Identify and localise biological material of
interest to researchers, build a critical mass of rare disease
sample collections, distribute high quality material and as-
sociated data to users, promote best-practice guidelines
for biobanking activities, disseminate knowledge and
know-how to the scientific community through training
courses, enhance collaboration with the medical and sci-
entific community in the field of rare diseases” [40].
Biobanks have become a crucial step in the transla-
tional process of the PPPM [41–43]. Since the number
of rare disease patients in each country is rather small,
especially for clinical trials and development of new
treatments, the use of biobank samples within networks
will facilitate better management of rare disease patients
[44]. To be able to use biomarkers as diagnostic tools in
personalized medicine, there are challenges such as high
cost of technology, management of high-throughput
data and education of healthcare professionals for inter-
pretation of omics data. Furthermore, ethical and legal
guidelines supporting the use of genomics technologies
will highly facilitate the personalized medicine approach
in RDs.
Conclusions
Personalized medicine has a high potential in translating
research results to clinical practice. Given the fact that
undiagnosed diseases still constitute the largest portion
of the rare diseases cohorts, advances in the high-
throughput omics technologies will enable identification
of better diagnostic and prognostic biomarkers. Charac-
terizing diseases at the molecular level helps to unravel
biochemical pathways that are potential drug targets.
However, the basic intrinsic problem is that the analysis
of large cohort of rare disease samples is quite difficult
as there are limited reported patients. This difficulty
could only be overcome by national and international
collaborative efforts and multicenter data sharing.
Education of healthcare personnel, policymakers, and
awareness raising in the general public is needed to
realize the goals of personalized medicine.
In summary, in the next 20 years, personalized medi-
cine will be at the forefront of clinical applications, and
customizing the individualized treatment will be guided
by the individual’s specific biomarker panels. Especially
in rare diseases where early diagnosis and treatment is
still a bottleneck, a personalized medicine approach will
have a high impact on increasing the quality of medical
care of rare disease patients.
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